Enterome Secures $19M to Accelerate Breakthrough Immunotherapies in Cancer and Immune Disease Treatment

Enterome, a clinical-stage biopharmaceutical company at the forefront of breakthrough immunomodulatory therapies, proudly announces a funding milestone with a successful raise of $19 million. This significant infusion of capital underscores the confidence that investors have in Enterome’s pioneering approach to drug discovery and its robust platform focused on bacterial mimicry. By leveraging the unique power of the gut microbiome, Enterome analyzes millions of bacterial proteins in continuous dialogue with the human body to uncover new biological insights, ultimately leading to the discovery of innovative treatments for cancer and immune diseases. The funds will accelerate the company’s current pipeline development, including the advancement of OncoMimics™ peptide-based immunotherapies tailored for cancer treatment. Notably, EO2463 is demonstrating promise in its Phase 2 clinical trial for indolent non-Hodgkin lymphoma, with early indications of a favorable safety profile and encouraging signs of efficacy, while EO2401, which has successfully completed a Phase 2 trial in patients with recurrent glioblastoma, is poised for further pivotal studies in collaboration with a pharmaceutical partner. The additional capital will support the expansion of these clinical programs, bolster preclinical research efforts, and facilitate strategic partnerships critical to Enterome’s mission. By nurturing a targeted and innovative approach to drug discovery, the company is well-positioned to address unmet medical needs and transform patient outcomes. This funding round not only validates the promise of Enterome’s scientific vision but also heralds a new chapter in the quest for pioneering immunomodulatory treatments that can reshape the landscape of oncology and immunotherapy.